GOLDENWELL BIOTECH, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GOLDENWELL BIOTECH, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $139 | May 15, 2025 |
| FY2024 | Dec 31, 2023 | $1.8K | May 15, 2025 |
| FY2022 | Dec 31, 2022 | $0 | Apr 13, 2023 |
| FY2022 | Dec 31, 2021 | $16.0K | Apr 13, 2023 |
| FY2020 | Dec 31, 2020 | $0 | Jul 23, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Jul 23, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $260 | Apr 12, 2024 |
| FY2023 | Dec 31, 2022 | $47.8K | Apr 12, 2024 |
| FY2021 | Dec 31, 2021 | $16.0K | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 6, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $64 | May 15, 2025 |
| FY2023 | Dec 31, 2023 | $73 | Apr 12, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $8.4K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 6, 2023 |
| FY2020 | Dec 31, 2019 | $0 | Jul 23, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($131.5K) | May 15, 2025 |
| FY2023 | Dec 31, 2023 | ($20.8K) | Apr 12, 2024 |
| FY2023 | Sep 30, 2023 | ($35.4K) | Apr 12, 2024 |
| FY2023 | Jun 30, 2023 | ($27.1K) | Apr 12, 2024 |
| FY2023 | Mar 31, 2023 | ($33.6K) | Apr 12, 2024 |
| FY2023 | Dec 31, 2022 | ($920.3K) | Apr 12, 2024 |
| FY2022 | Sep 30, 2022 | ($4.6K) | Apr 13, 2023 |
| FY2022 | Jun 30, 2022 | ($26.8K) | Apr 13, 2023 |
| FY2022 | Mar 31, 2022 | ($33.4K) | Apr 13, 2023 |
| FY2021 | Dec 31, 2021 | ($29.5K) | Feb 6, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($123.1K) | May 15, 2025 |
| FY2023 | Dec 31, 2023 | ($20.8K) | Apr 12, 2024 |
| FY2023 | Dec 31, 2022 | ($920.3K) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($118.3K) | Apr 13, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $126.7K | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | $6.4K | Feb 6, 2023 |
| FY2020 | Dec 31, 2019 | $2.6K | Jul 23, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($123.1K) | May 15, 2025 |
| FY2024 | Dec 31, 2023 | ($113.2K) | May 15, 2025 |
| FY2023 | Dec 31, 2022 | ($1.07M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($205.1K) | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($6.3K) | Feb 6, 2023 |
| FY2020 | Dec 31, 2019 | ($2.3K) | Jul 23, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $224.2K | May 15, 2025 |
| FY2024 | Dec 31, 2023 | $228.1K | May 15, 2025 |
| FY2023 | Dec 31, 2022 | $248.4K | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $461.0K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $248.6K | Feb 6, 2023 |
| FY2020 | Dec 31, 2019 | $246.6K | Jul 23, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $271.4K | May 15, 2025 |
| FY2024 | Dec 31, 2023 | $143.8K | May 15, 2025 |
| FY2023 | Dec 31, 2022 | $46.8K | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | $159.3K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 6, 2023 |
| FY2020 | Dec 31, 2019 | $0 | Jul 23, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($47.2K) | May 15, 2025 |
| FY2024 | Dec 31, 2023 | $84.3K | May 15, 2025 |
| FY2023 | Sep 30, 2023 | $105.5K | Apr 12, 2024 |
| FY2023 | Jun 30, 2023 | $140.9K | Apr 12, 2024 |
| FY2023 | Mar 31, 2023 | $168.0K | Apr 12, 2024 |
| FY2024 | Dec 31, 2022 | $201.6K | May 15, 2025 |
| FY2022 | Sep 30, 2022 | $237.0K | Apr 13, 2023 |
| FY2022 | Jun 30, 2022 | $241.5K | Apr 13, 2023 |
| FY2022 | Mar 31, 2022 | $268.3K | Apr 13, 2023 |
| FY2022 | Dec 31, 2021 | $301.7K | Apr 13, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.36M) | May 15, 2025 |
| FY2024 | Dec 31, 2023 | ($1.23M) | May 15, 2025 |
| FY2023 | Dec 31, 2022 | ($1.11M) | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | ($125.7K) | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($8.6K) | Feb 6, 2023 |
| FY2020 | Dec 31, 2019 | ($2.3K) | Jul 23, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $46.0K | Apr 13, 2023 |
| FY2022 | Dec 31, 2021 | $213.6K | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $248.6K | Feb 6, 2023 |
| FY2021 | Dec 31, 2019 | $246.6K | Apr 1, 2022 |
| FY2020 | Dec 31, 2018 | $0 | Jul 23, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | May 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | May 15, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 99.00M | May 15, 2025 |
| FY2024 | Dec 31, 2023 | 99.00M | May 15, 2025 |
| FY2023 | Dec 31, 2022 | 99.00M | Apr 12, 2024 |
| FY2022 | Dec 31, 2021 | 91.50M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | 91.50M | Feb 6, 2023 |
| FY2020 | Dec 31, 2019 | 80.00M | Jul 23, 2021 |